Brainstorm Cell Therapeutics, Inc. (BCLI)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Brainstorm Cell Therapeutics, Inc. chart...

About the Company

brainstorm cell therapeutics inc. (nasdaq:bcli), is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as als (lou gehrig's disease), multiple sclerosis (ms) and parkinson’s disease (pd). these diseases have limited treatment options and as such represent unmet medical needs. nurown™ is brainstorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (msc) into neurotrophic factor (ntf)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. our platform technology essentially converts mscs into living drug delivery system for ntfs. we have obtained proof-of-concept in a variety of animal models of neurodegenerative diseases, including parkinson's, huntington's, als, ms, and peripheral nerve injury. we have completed two single-arm clinical trials in als patients, conducted in israel, which have demonstr

$M

Total Revenue

24

Employees

$15M

Market Capitalization

-0.81

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $BCLI News

BCLI: Unveils Plans for Phase 3b Trial of NurOwn® in ALS…

12d ago, source: Zacks Small Cap Research on MSN

BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Phase 3b Trial Design Announced; SPA Submitted to the FDA On March 4, 2024, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) presented a poster ...

New ALS Treatments Face Regulatory Uncertainty

14d ago, source: BioSpace

Despite the approval of two novel therapies for this uniformly fatal neurodegenerative disease, experts say regulatory standards and expectations are still evolving.

Zacks Launched the Israel 150 Platform

6d ago, source:

Zacks Investment Research, a leading provider of investment-related data, research, and commentary, proudly announces the launch of Zacks Israel 150 - This new platform focuses on Israeli companies ...

Optimistic Buy Rating for Lineage Cell Therapeutics Amid Pipeline Progress and Strategic Partnerships

10d ago, source:

Mayank Mamtani, an analyst from B.Riley Financial, reiterated the Buy rating on Lineage Therap (LCTX – Research Report). The associated ...

FDA approves expanded use of Bristol Myers CAR T-cell therapy

3d ago, source: Seeking Alpha on MSN

The U.S. Food and Drug Administration (FDA) has approved Bristol Myers Squibb's (NYSE:BMY) Breyanzi as the first and only CAR T-cell therapy for adults with ... Finally Trending Up Karuna Therapeutics ...

Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference

13d ago, source: Business Insider

March 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq ... KER-050 (elritercept), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...